<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00103428</url>
  </required_header>
  <id_info>
    <org_study_id>V-0039</org_study_id>
    <nct_id>NCT00103428</nct_id>
  </id_info>
  <brief_title>Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer</brief_title>
  <official_title>A Phase 1/2a Dose-Escalation Trial of Intravenous CG7870 in Combination With Docetaxel in Chemotherapy-Na√Øve Patients With Metastatic Hormone-Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cell Genesys</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cell Genesys</source>
  <brief_summary>
    <textblock>
      V-0039 is a Phase 1/2 dose escalation trial of CG7870 in combination with Docetaxel in&#xD;
      metastatic hormone-refractory patients who have not received chemotherapy.&#xD;
&#xD;
      All patients will receive docetaxel. In the dose escalation phase of the study, patients will&#xD;
      receive treatment intravenously with CG7870 at one of up to four dose levels. In the Phase 2&#xD;
      portion of this study, additional patients will be added at the maximum tolerated dose that&#xD;
      is determined in Phase 1.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2004</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metastatic hormone refractory prostate cancer</measure>
  </primary_outcome>
  <enrollment>69</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CG7870</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy&#xD;
             (after discontinuation of anti-androgen therapy)&#xD;
&#xD;
          -  Detectable metastases by bone scan, and/or CT scan, and/or MRI, and/or CXR&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Transitional cell, small cell, neuroendocrine, or squamous cell prostate cancer&#xD;
&#xD;
          -  History of deep vein thrombosis or pulmonary embolus&#xD;
&#xD;
          -  Patients taking anticoagulants (such as coumadin or Heparin). The use of aspirin while&#xD;
             on study is acceptable.&#xD;
&#xD;
          -  History of a bleeding disorder or recent clinically significant bleeding&#xD;
&#xD;
          -  Seropositive for HIV&#xD;
&#xD;
          -  History of Hepatitis B, Hepatitis C, or chronic liver disease&#xD;
&#xD;
          -  Prior gene therapy or immunotherapy&#xD;
&#xD;
          -  Prior chemotherapy for prostate cancer&#xD;
&#xD;
          -  Radiation therapy within 4 weeks of the first treatment.&#xD;
&#xD;
          -  History of myocardial infarction within 6 months of the first treatment&#xD;
&#xD;
          -  History of cerebrovascular accident&#xD;
&#xD;
          -  History of previous malignancy, except for the following: adequately treated basal&#xD;
             cell or squamous cell skin cancer, superficial bladder cancer, adequately treated&#xD;
             Stage I or II cancer currently in complete remission, or any other cancer that has&#xD;
             been in complete remission for at least 5 years&#xD;
&#xD;
          -  Evidence of active prostatitis&#xD;
&#xD;
          -  Known hypersensitivity to docetaxel or to other drugs formulated with polysorbate 80&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mary Crowley Medical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2006</verification_date>
  <study_first_submitted>February 8, 2005</study_first_submitted>
  <study_first_submitted_qc>February 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2005</study_first_posted>
  <last_update_submitted>January 31, 2006</last_update_submitted>
  <last_update_submitted_qc>January 31, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2006</last_update_posted>
  <keyword>chemotherapy</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>hormone refractory</keyword>
  <keyword>chemotherapy naive</keyword>
  <keyword>dose escalation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

